Zang Yaning, Zhang Yongni, Lai Xigui, Yang Yujie, Guo Jiabao, Gu Shanshan, Zhu Yi
Department of Kinesiology, Shanghai University of Sport, Shanghai, China.
School of Health Sciences, Duquesne University, Pittsburgh, PA, USA.
Evid Based Complement Alternat Med. 2021 Oct 29;2021:3671800. doi: 10.1155/2021/3671800. eCollection 2021.
This study was aimed to summarize and analyze the quality of the available evidence in systematic reviews (SRs) of repetitive transcranial magnetic stimulation (rTMS) on the non-motor cortex (non-M1) for neuropathic pain (NP) through an evidence mapping approach.
We follow the Global Evidence Mapping (GEM) methodology. Searches were conducted in PubMed, EMBASE, Epistemonikos, and the Cochrane Library. The study type was restricted to SRs with or without meta-analysis. All literature published before January 23, 2021, were included. The methodological quality of the included SRs was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2). Data were extracted according to a defined population-intervention-comparison-outcome (PICO) framework from primary studies that included SRs. The same PICO was categorized into PICOs according to interventions (stimulation target, frequency, number of sessions (short: 1-5 sessions, medium: 5-10 sessions, and long: >10 sessions)) and comparison (sham rTMS or other targets). The evidence mapping was presented in tables and a bubble plot.
A total of 23 SRs were included. According to the AMSTAR-2, 20 SRs scored "very low" in terms of methodological quality, 2 SRs scored "low," and 1 SR scored "high." A total of 17 PICOs were extracted. The dorsolateral prefrontal cortex (DLPFC) is the most studied of the non-motor cortex targets. PICOs of DLPFC, premotor cortex (PMC), frontal cortex, and secondary somatosensory cortex (S2) were mainly categorized with a "potentially better" conclusion. High-frequency (5-20 Hz) rTMS of non-M1 usually lead to "potentially better" conclusions.
DLPFC, PMC, frontal cortex, and S2 seem to be promising new targets for rTMS treatment of certain NP. Evidence mapping is a useful and reliable methodology to identify and present the existing evidence gap that more research efforts are necessary in order to highlight the optimal stimulation protocols for non-M1 targets and standardize parameters to fill the evidence gaps of rTMS. Further investigation is advised to improve the methodological quality and the reporting process of SRs.
本研究旨在通过证据图谱法,总结和分析重复经颅磁刺激(rTMS)作用于非运动皮层(非M1)治疗神经性疼痛(NP)的系统评价(SRs)中现有证据的质量。
我们遵循全球证据图谱(GEM)方法。在PubMed、EMBASE、Epistemonikos和Cochrane图书馆进行检索。研究类型限于有或没有meta分析的SRs。纳入2021年1月23日前发表的所有文献。使用系统评价评估测量工具(AMSTAR-2)评估纳入的SRs的方法学质量。根据定义的人群-干预-对照-结局(PICO)框架,从包括SRs的原始研究中提取数据。相同的PICO根据干预措施(刺激靶点、频率、疗程数(短:1-5个疗程,中:5-10个疗程,长:>10个疗程))和对照(假rTMS或其他靶点)进行分类。证据图谱以表格和气泡图形式呈现。
共纳入23篇SRs。根据AMSTAR-2,20篇SRs在方法学质量方面评分为“极低”,2篇评分为“低”,1篇评分为“高”。共提取17个PICO。背外侧前额叶皮层(DLPFC)是研究最多的非运动皮层靶点。DLPFC、运动前皮层(PMC)、额叶皮层和次级体感皮层(S2)的PICO主要归类为“可能更好”的结论。非M1的高频(5-20Hz)rTMS通常导致“可能更好”的结论。
DLPFC、PMC、额叶皮层和S2似乎是rTMS治疗某些NP的有前景的新靶点。证据图谱是一种有用且可靠的方法,可识别和呈现现有的证据差距,即需要更多研究努力来突出非M1靶点的最佳刺激方案并标准化参数,以填补rTMS的证据空白。建议进一步研究以提高SRs的方法学质量和报告过程。